1. Design and synthesis of H 2 S-donor hybrids: A new treatment for Alzheimer's disease?
- Author
-
Sestito S, Pruccoli L, Runfola M, Citi V, Martelli A, Saccomanni G, Calderone V, Tarozzi A, and Rapposelli S
- Subjects
- Animals, Antioxidants chemical synthesis, Antioxidants chemistry, Cell Line, Dose-Response Relationship, Drug, Drug Design, Humans, Hydrogen Sulfide chemical synthesis, Hydrogen Sulfide chemistry, Isothiocyanates chemical synthesis, Isothiocyanates chemistry, Lipopolysaccharides antagonists & inhibitors, Lipopolysaccharides pharmacology, Mice, Microglia drug effects, Molecular Structure, Neurons drug effects, Neuroprotective Agents chemical synthesis, Neuroprotective Agents chemistry, Rivastigmine chemical synthesis, Rivastigmine chemistry, Structure-Activity Relationship, Sulfides chemical synthesis, Sulfides chemistry, Sulfides pharmacology, Sulfoxides, Thiocyanates chemical synthesis, Thiocyanates chemistry, Thiocyanates pharmacology, Alzheimer Disease drug therapy, Antioxidants pharmacology, Hydrogen Sulfide pharmacology, Isothiocyanates pharmacology, Neuroprotective Agents pharmacology, Rivastigmine pharmacology
- Abstract
Hydrogen sulphide (H
2 S) is an endogenous gasotransmitter, largely known as a pleiotropic mediator endowed with antioxidant, anti-inflammatory, pro-autophagic, and neuroprotective properties. Moreover, a strong relationship between H2 S and aging has been recently identified and consistently, a significant decline of H2 S levels has been observed in patients affected by Alzheimer's disease (AD). On this basis, the use of H2 S-donors could represent an exciting and intriguing strategy to be pursued for the treatment of neurodegenerative diseases (NDDs). In this work, we designed a small series of multitarget molecules combining the rivastigmine-scaffold, a well-established drug already approved for AD, with sulforaphane (SFN) and erucin (ERN), two natural products deriving from the enzymatic hydrolysis of glucosinolates contained in broccoli and rocket, respectively, endowed both with antioxidant and neuroprotective effects. Notably, all new synthetized hybrids exhibit a H2 S-donor profile in vitro and elicit protective effects in a model of LPS-induced microglia inflammation. Moreover, a decrease in NO production has been observed in LPS-stimulated cells pre-treated with the compounds. Finally, the compounds showed neuroprotective and antioxidant activities in human neuronal cells. The most interesting compounds have been further investigated to elucidate the possible mechanism of action., (Copyright © 2019 Elsevier Masson SAS. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF